Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : RLS-1496
Therapeutic Area : Dermatology
Study Phase : IND Enabling
Recipient : Rubedo Life Sciences
Deal Size : Undisclosed
Deal Type : Partnership
Rubedo Pulls in $40M Series A to Advance Atopic Dermatitis Candidate Targeting Aging Cells
Details : The financing will be utilized to fund the progress of the company’s primary candidate, RLS-1496, for treating patients with atopic dermatitis and chronic psoriasis.
Brand Name : RLS-1496
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 22, 2024
Lead Product(s) : RLS-1496
Therapeutic Area : Dermatology
Highest Development Status : IND Enabling
Recipient : Rubedo Life Sciences
Deal Size : Undisclosed
Deal Type : Partnership
LOOKING FOR A SUPPLIER?